Phase IV CoVigi trial: in 204 pts with solid #cancer on therapy, 92% developed anti-S antibodies after 2nd BNT162b2 dose; all seroconverted by 6 mo. Chemotherapy impaired both humoral & cellular responses, while prior COVID-19 infection boosted immunity. journals.sagepub.com/doi/epdf/10....

Multicenter Mexican cohort (n=477) of young women with #BreastCancer (≤40 yrs): 62% followed a poor long-term QoL trajectory over 5 yrs, with declines in sexual health & future perspective. HER2+ status & public insurance linked to better QoL outcomes. journals.sagepub.com/doi/epdf/10....

Retrospective study of 110 high-risk rectal cancer pts: total neoadjuvant therapy achieved organ preservation in ~50% with 3-yr DFS 75.7% OS 92.4%. Watch & wait strategy gave superior outcomes vs non-pCR pts. TNT supports durable survival & bowel function journals.sagepub.com/doi/epdf/10....

Study in advanced #GastricCancer: flow cytometry of peritoneal lavage showed CD44+/CD326+ tumor cells correlate with response to repeated intraperitoneal perfusion chemotherapy (RIPPENC). Lower levels linked to resection eligibility & longer survival. journals.sagepub.com/doi/epdf/10....

Phase Ib study of xevinapant + avelumab in advanced solid tumours & #NSCLC: RP2D established at 200 mg/day, safety manageable. In NSCLC (n=38), ORR 10.5% (not superior to avelumab alone). Biomarker analyses highlight immune signatures tied to response journals.sagepub.com/doi/epdf/10....

Systematic review & meta-analysis (9 RCTs) in advanced gastric cancer: #immunotherapy + chemo did not improve OS/PFS vs chemo alone in pts with low PD-L1 (CPS<1 or <5). Dual antibody regimens showed PFS benefit (HR 0.64), warranting further study. Read: journals.sagepub.com/doi/epdf/10....

Retrospective study of 213 late-stage cancer pts in Jordan evaluates #NGS. Clinically significant alterations in 42% (KRAS, PIK3CA, ERBB2, EGFR, BRCA). PFS markedly improved with NGS-guided therapy (HR 0.216) though cost & drug access remain major barriers journals.sagepub.com/doi/epdf/10....

#TopReadTuesday from TAM: Aberrant DNA methylation is a hallmark of cancer, driving initiation, progression & therapy resistance. This review details clinical impacts from MMR gene silencing to BRCA1 methylation loss under treatment pressure. 🔗 journals.sagepub.com/doi/epdf/10....

In NSCLC patients with bone metastases, those receiving palliative RT during ICI treatment had significantly better survival: median OS 16 mo vs 3 mo; PFS also improved. These findings support a synergistic role for RT with immunotherapy. 🔗 journals.sagepub.com/doi/epdf/10....

In real-world data from 147 advanced BTC patients refractory to gem/cis, second-line 5-FU-based therapy showed modest survival (median OS 4.8 mo). FOLFOX had comparable efficacy but better safety than Nal-IRI/FL or FOLFIRINOX—supporting role as 2L option. journals.sagepub.com/doi/epdf/10....

New real-world data from China compares flumatinib vs nilotinib as 1L treatment for chronic phase CML (n=165): 🔹 Similar MMR at 12 mo (85.1% vs 88.2%) 🔹 Nilotinib led to higher MR4 at all timepoints 🔹 Flumatinib had fewer metabolic/liver AEs 🔗 journals.sagepub.com/doi/epdf/10....

In mRCC, second-line ICI vs TKI showed similar OS (44.8 vs 41.1 mo; p=0.446). But in NLR-high patients, TKI→ICI led to better survival vs TKI→TKI. Bone mets and nephrectomy history also influenced outcomes. 👉 NLR may guide 2L therapy: doi.org/10.1177/1758...

In a cohort of 514 cancers, high ICOS expression (14%) was linked to elevated PD-1, PD-L1 & CTLA-4 RNA (all p<0.05) but not survival in ICI-treated or immunotherapy-naïve patients. Suggests ICOS ≠ prognostic, but may guide combo ICI strategies. doi.org/10.1177/1758...

📌 In a Chinese LCNEC cohort (n=151), median OS was 17.8 mo. Adjuvant chemo post-surgery reduced distant spread & improved 2-yr OS (37.1% vs 79.9%, p<0.001). Immunochemotherapy outperformed chemo alone in advanced disease. doi.org/10.1177/1758...

📊 In non-resectable stage III melanoma, T-VEC and IL-2 showed no significant differences in PFS (5.0 mo), OS (34.0 mo), or response rates. Both were well tolerated with minimal AEs. Real-world data to guide intralesional therapy choice. doi.org/10.1177/1758...

3 patients with metastatic KRAS-wildtype PDAC showed prolonged response to osimertinib after EGFR exon 19 deletion was found via NGS. Early molecular & metabolic responses seen; disease controlled for 6, 8, and 17 months. A case for rare mutation testing journals.sagepub.com/doi/epdf/10....

First reported case of coma from luminal breast cancer brain mets reversed without radiation: patient treated w/ nasogastric abemaciclib + fulvestrant post-surgery. Seizures resolved, imaging improved, full functional recovery—patient returned to work journals.sagepub.com/doi/epdf/10....

Checkpoint inhibitors are now standard in advanced HCC, but resistance is common. This review explores how TACE, radiation, and novel combos (triplets, bispecifics, vaccines) may expand efficacy and indications. Read here: journals.sagepub.com/doi/epdf/10....

🧵April is National Cancer Control Month. We're highlighting research that reflects commitment to improving cancer care—through innovative therapies, cost-effectiveness, and global equity. Here are some articles from the past year ⬇️

🔍 A new review explores the toxicity profiles and management strategies of emerging antibody–drug conjugates (ADCs) in breast cancer. From ILD to neutropenia, understanding these effects is key to maximizing benefit across all BC subtypes Read here: journals.sagepub.com/doi/epdf/10....

(1/6) Freedom of expression and inquiry are integral to education and we work to uphold these principles in everything we publish. Learn how we're amplifying voices impacted by censorship and strengthening academic freedom 👇 Read the report: bit.ly/iwi24

🩻Breast imaging in Thai transgender women aged 40+ (avg 16 yrs HRT) showed high breast density and low abnormality rates. Most (80%) had augmentation; 94% of findings were benign or negative. Supports need for dual-modality screening. Read here: journals.sagepub.com/doi/epdf/10....

📘 A practical guide on adjuvant CDK4/6 inhibitors for HR+, HER2− early breast cancer, integrating real-world insights on abemaciclib vs ribociclib, toxicity management, and care delivery—rooted in monarchE and NATALEE findings. 🔗 journals.sagepub.com/doi/epdf/10....

🩺 After TACE conversion therapy for unresectable HCC, surgical resection (SR) offered better OS and DFS than microwave ablation (MWA) (OS: 10.6 vs 5.8 yrs; HR: 1.83; p < 0.001). But in patients <45 or meeting Milan criteria, outcomes were comparable. 🔗 journals.sagepub.com/doi/epdf/10....

🧬 Extensive-stage small-cell lung cancer: Immune checkpoint inhibitors like atezolizumab & durvalumab have improved survival when added to chemotherapy. New strategies—lurbinectedin, anti-DLL3 antibodies & subtype-based approaches—are in development 🔗 journals.sagepub.com/doi/epdf/10....

📊 A new TBR (tumor burden + radiologic features) score stratified intermediate-stage HCC patients undergoing TACE-MWA into low-, middle-, and high-risk groups, showing superior OS prediction vs existing staging systems (HRs: 0.69–1.63). 🔗 journals.sagepub.com/doi/epdf/10....

🩺 In LSCC patients treated with necitumumab + gemcitabine/cisplatin, skin disorder within 30 days was linked to longer OS (434 vs 278 days, p=0.0201) and PFS. Minocycline use in those with rash improved TTF (148 vs 101 days, p=0.0495). 🔗 journals.sagepub.com/doi/epdf/10....

🧬 In KRAS G12C-mutant advanced NSCLC, immunotherapy remains a cornerstone, with emerging strategies exploring dual checkpoint blockade and combinations with KRAS G12C inhibitors like sotorasib and adagrasib. 🔗 journals.sagepub.com/doi/epdf/10....

🧮 A validated scoring system predicts 5-year survival in EGFRm NSCLC patients treated with EGFR-TKIs. Survival ranged from 1.5% to 23.4% depending on clinical risk factors; findings were confirmed in an external cohort. 🔗 journals.sagepub.com/doi/epdf/10....

ORCHARD (module 10): Osi + Dato-Dxd post 1L Osi ❇️ ORR 36 - 43% ❇️ mPFS 9.5 - 11.7m ❇️ DoR longer in 6mg/kg grp ❗️ 65% Dato dose reduction ❗️ 60% Dato dose interr 💭 Active combination 💭 Toxic+ 💭 Not biomarker directed #ELCC25

MARIPOSA final OS analysis ❇️ Significant HR 0.75 ❇️ 9% 3yr benefit ❇️ Projected mOS 4 years ❇️ Longer control of CNS disease ❗️At the cost of toxicity ❗️No data on duration of toxicity ❗️PROM and QoL data important More effective than Osimertinib Most suitable for higher risk pts #ELCC25

BAY88 in HER2mut NSCLC Lower ORR, but similar DoR, if prior HER2 ADC (as opposed to treatment naive) #ELCC25

🧪 Meta-analysis of TROPiCS-02 and EVER-132-002 confirms that sacituzumab govitecan significantly outperforms treatment of physician’s choice in HR+/HER2− mBC: • PFS: HR 0.62 • OS: HR 0.66 • ORR: RR 1.45 • CBR: RR 1.59 • DOR: HR 0.55 🔗 journals.sagepub.com/doi/epdf/10....

🧬 A custom nCounter fusion panel achieved 98.2% conclusive results and 100% specificity in sarcoma diagnosis across 56 cases in Brazil. This low-cost, high-accuracy method could expand access to precision diagnostics in resource-limited settings. 🔗 journals.sagepub.com/doi/epdf/10....

💥 Now open for submissions: Our new Special Collection in TAM explores the mechanisms, management, and future directions of T-cell engager toxicities in solid tumours. Submit your research: journals.sagepub.com/topic/collec... 🗓️ Deadline: 7 Sept 2025

🦴 Bone metastasis in follicular dendritic cell sarcoma (FDCS)—a rare case in a rare disease. This report details nearly a decade of disease progression & treatment, alongside a systematic review of FDCS cases with bone metastases. 🔗 Read more: journals.sagepub.com/doi/epdf/10....

A real-world study on trastuzumab deruxtecan (T-DXd) in Chinese patients with HER2-positive & HER2-low advanced breast cancer shows promising efficacy with controllable adverse events across multiple centers. 🔗 Read more: journals.sagepub.com/doi/epdf/10....

Timing of systemic anticancer therapy (SACT) affects cancer vaccine immunogenicity. This review examines how chemotherapy, ICIs, and steroids impact vaccine efficacy, highlighting the need for optimal timing in treatment. 🔗 Read more: journals.sagepub.com/doi/epdf/10....